P. Jurka

Treatment of fibroadenomatosis in 14 cats with aglepristone – changes in blood parameters and follow-up

Fourteen female cats with fibroadenomatosis were treated with aglepristone, and the effectiveness of the treatment and its effect on selected haematological and blood chemistry parameters were studied. The cats were monitored for 12 months after the end of the treatment. Complete remission of the clinical signs was achieved on average 3·9 weeks after the treatment began; the success of the treatment confirmed the clinical diagnosis of fibroadenomatosis. During the course of the treatment the cats’ haematological parameters returned to normal. In cats that had previously been treated with longacting medroxyprogesterone acetate, treatment with aglepristone for five weeks was recommended. Cases of fibroadenomatosis reappearing after a few months should be regarded as new disease rather than a relapse. Six cats were subsequently mated and four gave birth to one or more litters; all the pregnancies proceeded normally with no clinically evident fibroadenomatosis. The other eight cats underwent ovariohysterectomy soon after the aglepristone treatment was completed.

Hypospadias in six dogs.

Six dogs, five males and one hermaphrodite, were diagnosed with hypospadias. Two of the five males had the penile form of the condition, two had the perineal form and one had the glandular form; the hermaphrodite had the scrotal form. The hermaphrodite had no prostate gland and no right testicle; it had a normal right ovary and horn of the uterus but the left horn was joined to the testicle. Its karyotype showed 78 chromosomes, all in metaphase, and two typical sex chromosomes X and Y.